Tecfidera
Named-patient access overview. Tecfidera is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Tecfidera (dimethyl fumarate) is an oral fumaric acid ester developed by Biogen that is thought to act primarily through activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant response pathway and modulation of pro-inflammatory cytokine signalling. The US Food and Drug Administration approved Tecfidera in March 2013 for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Dosing is initiated at 120 mg by mouth twice daily for the first seven days, then increased to the maintenance dose of 240 mg twice daily, taken with or without food. Tecfidera is prescribed by neurology and managed in an outpatient setting, with periodic complete blood counts and clinical monitoring for lymphopenia and the rare risk of progressive multifocal leukoencephalopathy.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Tecfidera
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Tecfidera is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Tecfidera in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Tecfidera
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.